O-RADS referral
When Should O-RADS Findings Prompt Gynecologic Oncology Referral?
A concise clinician guide for using O-RADS risk language in Gyn Onc consult decisions.
Quick answer
O-RADS Referral
- O-RADS risk categories help translate adnexal imaging into referral urgency. *
- High-risk O-RADS findings support Gyn Onc referral or discussion when surgery, biopsy route, or disposition may change. *†
- Incomplete or vague imaging often needs better characterization before Gyn Onc can answer the right question. *
Consult Gyn Onc when
High-Risk O-RADS Context
- O-RADS 4/5 or report language strongly suggests malignancy. *
- O-RADS concern is paired with ascites, peritoneal disease, suspicious nodes, or cancer symptoms. *†
- The next decision is surgical planning, staging, biopsy route, or admission/disposition.
Workup first when
Better First Steps
- The O-RADS category is missing and the report is too vague for risk stratification.
- CT found an adnexal lesion but pelvic US is the better next characterization step. *
- Imaging is low-risk and follow-up or surveillance is the main question.
Common pitfall
Do Not Treat Vague Imaging as Risk Stratification
If the report does not give enough risk language, the next move may be better imaging, not a premature consult.
FAQ
O-RADS Questions
What O-RADS score usually needs Gyn Onc?
High-risk O-RADS categories are more likely to justify referral or discussion, especially if surgery or biopsy route may change. *†
What if CT suggests a mass but no O-RADS score exists?
Pelvic ultrasound with O-RADS risk stratification may be the better next step if the patient is stable and disposition does not depend on Gyn Onc today. *
Does O-RADS replace clinical judgment?
No. Use O-RADS with symptoms, exam, menopausal status, pathology, acuity, and local referral pathways.
References
Educational tool only. SIC provides clinician-facing educational consult-triage references. SIC does not diagnose, treat, prevent, cure, or mitigate disease and is not a substitute for clinical judgment, local guidelines, institutional referral pathways, or recommendations from your gynecologic oncology department. See disclaimer.